Merck and Samsung Bioepis Launch Biosimilar Early, After SCOTUS Ruling

Generic Line
A A
Samsung Bioepis and Merck announced the U.S. launch of Renflexis (infliximab-abda), a biosimilar of Janssen’s Remicade (infliximab).

To View This Article:

Login

Subscribe To Generic Line